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On Predictors of
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The clinical diagnostic hallmark of hypertrophic cardiomy-
opathy (HCM) is unexplained cardiac hypertrophy, com-
monly found on an echocardiogram and in unfortunate
occasions, in an autopsy. The latter is most tragic as HCM,
a relatively common disease (1) often presenting with
sudden cardiac death (SCD) in apparently healthy young
individuals (2,3). Indeed, HCM is considered the most
common cause of SCD in young competitive athletes (2).
The unexpected SCD of young athletic individuals in
conjunction with the results of earlier studies from major
referral centers, reporting an annual mortality rate of ap-
proximately 2% to 6% (3–5), led to the impression that
HCM is a relatively malignant disease. Population-based
studies, however, suggested a more benign course with an
annual mortality rate of approximately 1% (6–9). In the
largest series comprised of 744 patients, the annual mortal-
ity rate was 1.2% of which approximately half were sudden
unexpected deaths (9).
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In this issue of the Journal, Kofflard et al. (10) extend
their previous report (7) and present data on the clinical
outcome of 225 patients with HCM that were followed up
for a mean period of 8 years. The overall annual cardiac
mortality rate was 0.8% with SCD comprising the majority
of deaths. Among the potential predictors, only syncope was
associated with the risk of SCD. The results suggest a less
malignant course for HCM in the setting of conventional
therapy that may include surgical septal myectomy and
pacemaker implantation and are in accordance with the
result of previous population-based studies (6–9). Collec-
tively, the existing data suggests an annual cardiac mortality
rate of patients with HCM is about 1% with SCD com-
prising at least half and heart failure and stroke comprising
the remainder (9,11).
Death due to HCM, while uncommon, is often cata-
strophic, as it is often unexpected in young, apparently
healthy, athletic individuals. The challenges facing physi-
cians and patients alike are to identify those who are at risk
and to intervene to prevent SCD. Since HCM is a genetic
disease with a simple Mendelian inheritance and variable
penetrance, risk stratification often extends to the offspring
of an affected individual as well. During the past several
years, significant efforts have been made to accurately
identify those who are at a high risk of SCD. The results
have been complicated by the clinical and genetic hetero-
geneity of HCM as well the relatively small number of cases
in the studies. Nevertheless, several potential risk factors
have been identified (Table 1). In the Kofflard et al. (10)
study, only history of syncope was associated with SCD, a
finding that corroborates the results of previous studies
(3,12–14). In contrast, several other indices, previously
associated with the risk of SCD, such as age (3,9), family
history of SCD (3,13,15), magnitude of left ventricular
hypertrophy (16,17), and presence of ventricular tachycardia
on Holter monitoring (14,18) were not independent pre-
dictors of SCD. The apparent discrepancy may reflect the
relatively small number of SCD in the present study. There
were only 27 cardiovascular deaths of which 20 were SCD.
In addition, the results largely reflect the clinical practice
experience of the Thoraxcenter and, as often is the case in
such studies, no a priori criteria were implemented for
phenotypic characterization and interventions. As such,
Holter monitoring data were available in two-thirds of the
patients and invasive electrophysiologic studies were not
part of the study. Furthermore, patients received a variety of
pharmacologic and nonpharmacologic interventions, as
deemed clinically indicated, which may or may not con-
found the results of the study with regard to identification of
predictors of SCD. Finally, pathologic phenotypes, such as
myocyte disarray and interstitial fibrosis, previously associ-
ated with the risk factors for SCD (14,19,20), were not
included in the report. Nevertheless, the results are useful
and probably relevant to the day-to-day experience of many
clinicians who manage patients with HCM.
The seminal discovery of a R403Q mutation in the
beta-myosin heavy chain (MyHC) in a family with HCM
approximately 12 years ago (21) led to elucidation of
molecular genetic basis of HCM and subsequent identifi-
cation of a large number of mutations in 10 different
sarcomeric proteins (22). Today, the causal genes and
mutations have been identified for approximately two-thirds
of HCM cases (22,23). Mutations in genes encoding
beta-MyHC, myosin binding protein-C (MyBP-C) and
cardiac troponin T (cTnT) account for the vast majority of
HCM cases and the remainder are uncommon (22). Eluci-
dation of molecular genetic basis of HCM brought forth the
possibility of genetic risk stratification, independent of and
prior to the development of clinical phenotypes. The results
of genotype-phenotype correlation studies suggest that spe-
cific mutations impart a significant impact on phenotypic
expression of HCM including the risk of SCD (24,25). In
general, mutations in the beta-MyHC are associated with
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an earlier onset, more severe cardiac hypertrophy, and a
higher incidence of SCD than those in the MyBP-C
(26–28). The phenotype of patients with mutations in
cTnT is characterized by relatively mild hypertrophy but a
high incidence of SCD and extensive disarray (19,29).
While the diversity of causal genes and mutations is partially
responsible for the variability of clinical phenotype, there is
a significant degree of phenotypic variability among the
affected individuals within a family and among members of
families with identical causal mutations. Overall, the exist-
ing data suggest mutations exhibit highly variable clinical,
electrocardiographic, and echocardiographic manifestations
and no particular phenotype is mutation-specific (30).
In this issue of the Journal, Jongbloed et al. (31) describe
a large family with HCM caused by a novel missense
mutation (E62Q) in the gene coding for alpha-
tropomyosin. The phenotype is characterized by a high
incidence of SCD, affecting 9 out of the 18 mutation
carriers, at a relatively young age and a variable degree of
cardiac hypertrophy (31). Because mutations in the alpha-
tropomyosin are uncommon causes of HCM, only a few
genotype-phenotype correlation studies have been reported
previously. The results showed variable phenotypic expres-
sion but predominantly mild-to-moderate degree of cardiac
hypertrophy and a relatively benign prognosis (32,33), with
the exception of one report that described a high incidence
of SCD, despite a mild degree of cardiac hypertrophy (34).
The E62Q mutation described by Jongbloed et al. (31) is
clearly associated with a malignant phenotype in this par-
ticular family. However, what remains unknown and will
likely remain unknown (given the low frequency of individ-
ual causal mutations in HCM), is whether the observed
association is unique to this family or could be generalized
to additional HCM families. While HCM is a classic
single-gene disorder, its clinical phenotypes, including hy-
pertrophy and SCD, are complex phenotypes. No HCM
phenotype is strictly genetic or entirely environmental but is
the result of complex interplay between genetic and nonge-
netic factors. Specific factors that account for the variability
of the clinical and pathological phenotypes in HCM are not
well understood. Diverse causal genes and mutations, by
imparting different effects on the structure and function of
contractile sarcomeric proteins, account for part of the
variability of clinical phenotypes. In addition, modifier
genes, epigenetic factors (such as deoxyribonucleic acid
methylation and imprinting), epistasis (interactions between
genes), post-transcriptional and post-translation modifica-
tions of gene products, presence of concomitant diseases
(e.g., hypertension), compound heterozygosity, and envi-
ronmental factors are expected to affect phenotypic expres-
sion of HCM. Therefore, based on the results of genotype-
phenotype correlation study in a single family, one cannot
conclude that the high incidence of SCD reflects the impact
of the E62Q mutation. As authors suggest, topography of
the causal mutation (on the encoded protein) could signifi-
cantly impact the severity of the phenotype. This is best
exemplified in the case of mutations in sarcomeric proteins
leading to contrasting phenotypes of either hypertrophic or
dilated cardiomyopathy (35,36). Variability in the clinical
phenotype among individuals within a family implicate factors
other than the causal mutation, such as the modifier genes, in
influencing expression of clinical phenotypes in HCM (37).
Thus, association of the E62Q mutation with the risk of SCD,
while an important initial observation, should be considered
provisional pending confirmation in additional families.
The collective results of studies reported in this issue of
the Journal and the previous studies identify several poten-
tial predictors of SCD, albeit each has limited positive and
negative predictive values (Table 1). Despite the imperfect-
ness of the current data in predicting the risk of SCD, those
with syncope or multiple risk factors, which comprise about
one-fifth of patients with HCM (10,13) are considered at a
high risk of SCD and may benefit from prophylactic
interventions. Because ventricular fibrillation is likely to
constitute the primary mechanism of SCD in high-risk
individuals, implantation of an automatic internal
cardioverter-defibrillator (AICD) could prove to be effec-
tive. The results of a recent retrospective study support the
potential effectiveness of AICD implantation in prevention
of SCD in selected patients with HCM (38). Experimental
data also have raised the possibility of attenuation and
reversal of the arrhythmogenic substrate (i.e., cardiac hyper-
trophy and fibrosis, in animal models of HCM) (39,40).
These advances further underscore the need for accurate risk
identification and identification of those who are at risk of
SCD. The clinical utility of genotype-phenotype correlation
studies has been limited for various reasons, including
confounding effects of small size of the families, small
number of families with identical mutations, modifier genes,
nongenetic factors, and sometimes compound homozygosity
for the causal mutations (41,42). Studies in single families,
despite their limitations, could provide the initial impetus for
performing large-scale studies. In order to extend the results of
genotype-phenotype correlation studies to clinical practice
aiming to prevent SCD, large-scale studies in multiple families
are need. The ultimate goals are to establish a consensus in
delineating the prognostic significance of the causal mutations,
modifier genes, and nongenetic factors.
Table 1. Potential Risk Factors for SCD in HCM
History of SCD
Family history of premature death
“Malignant” causal mutations
“Malignant” modifier genes
History of syncope
Magnitude of left ventricular hypertrophy
Extent of myocyte disarray
Extent of interstitial fibrosis
Early onset of the disease
Myocardial ischemia on perfusion tomography
Abnormal blood pressure response to exercise
Presence of nonsustained VT on Holter
HCM  hypertrophic cardiomyopathy; SCD  sudden cardiac death; VT 
ventricular tachycardia.
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